Table 1:
Baseline and Tumor Characteristics
| Total n = 923 |
No invasion n = 642 |
IMVI only n = 59 |
EMVI only n = 163 |
Both n = 59 |
P-value | |
|---|---|---|---|---|---|---|
| Age, years | 69.0 (57.7–79.8) | 69.4 (57.8–79.8) | 74.9 (60.2–82.6) | 68.1 (58.0–78.6) | 65.9 (55.1–78.7) | 0.329 |
| Female gender | 487 (52.8%) | 342 (53.3%) | 35 (59.3%) | 83 (50.9%) | 27 (45.8%) | 0.481 |
| Caucasian | 826 (89.5%) | 575 (89.6%) | 55 (93.2%) | 143 (87.7%) | 53 (89.8%) | 0.782 |
| ASA score | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–3) | 0.314 |
| BMI, kg/m2 | 26.7 (23.2–30.7) | 26.8 (23.3–30.8) | 27.2 (23.1–31.7) | 26.4 (23.3–29.8) | 26.9 (22.7–33.2) | 0.797 |
| Inflammatory Bowel disease | 27 (2.9%) | 19 (3.0%) | 1 (1.7%) | 5 (3.1%) | 2 (3.4%) | 0.946 |
| Urgent admission | 99 (10.7%) | 66 (10.3%) | 8 (13.6%) | 16 (9.8%) | 9 (15.3%) | 0.566 |
| Bowel obstruction | 68 (7.4%) | 38 (5.9%) | 6 (10.2%) | 17 (10.4%) | 7 (11.9%) | 0.084 |
| Bowel perforation | 25 (2.7%) | 18 (2.8%) | 1 (1.7%) | 4 (2.5%) | 2 (3.4%) | 0.941 |
| Tumor location | 0.140 | |||||
| Right-sided | 479 (51.9%) | 336 (52.3%) | 38 (64.4%) | 82 (50.3%) | 23 (39.0%) | |
| Transverse colon | 83 (9.0%) | 60 (9.3%) | 3 (5.1%) | 12 (7.4%) | 8 (13.6%) | |
| Left-sided | 94 (10.2%) | 67 (10.4%) | 8 (13.6%) | 12 (7.4%) | 7 (11.9%) | |
| (Recto)sigmoid colon | 250 (27.1%) | 166 (25.9%) | 9 (15.3%) | 54 (33.1%) | 21 (35.6%) | |
| Multiple sites | 17 (1.8%) | 13 (2.0%) | 1 (1.7%) | 3 (1.8%) | 0 (0.0%) | |
| R0-resection | 890 (96.4%) | 625 (97.4%) | 57 (96.6%) | 154 (94.5%) | 54 (91.5%) | 0.057 |
| Tumor characteristics | ||||||
| Stage II disease | 465 (50.4%) | 367 (57.2%) | 33 (55.9%) | 51 (31.3%) | 14 (23.7%) | <0.001 |
| Tumor size | 5.0 (3.5–7.5) | 5.2 (3.5–7.7) | 4.7 (3.5–7.5) | 5.0 (3.5–7.0) | 5.3 (3.5–10.9) | 0.604 |
| High grade | 239 (26.1%) | 154 (24.2%) | 13 (22.4%) | 51 (31.3%) | 21 (36.2%) | 0.073 |
| T4 tumor | 237 (25.7%) | 130 (20.2%) | 12 (20.3%) | 67 (41.1%) | 28 (47.5%) | <0.001 |
| Lymphatic invasion | 376 (40.7%) | 194 (30.2%) | 27 (45.8%) | 107 (65.6%) | 48 (81.4%) | <0.001 |
| Perineural invasion | 211 (22.9%) | 90 (14.0%) | 15 (25.4%) | 69 (42.6%) | 37 (62.7%) | <0.001 |
| Lymph nodes examined | 21 (16–29) | 21 (16–29) | 21 (16–29) | 20 (16–29) | 23 (17–35) | 0.605 |
| <12 lymph nodes examined | 69 (7.5%) | 48 (7.5%) | 3 (5.1%) | 12 (7.4%) | 6 (10.2%) | 0.775 |
| Microsatellite instability | 0.061 | |||||
| High | 125 (13.5%) | 95 (14.8%) | 7 (11.9%) | 14 (8.6%) | 9 (15.3%) | |
| Low | 39 (4.2%) | 31 (4.8%) | 3 (5.1%) | 5 (3.1%) | 9 (0.0%) | |
| Stable | 392 (42.5%) | 251 (39.1%) | 32 (54.2%) | 79 (48.5%) | 30 (50.8%) | |
| Not tested | 367 (39.8%) | 265 (41.3%) | 17 (28.8%) | 65 (39.9%) | 20 (33.9%) | |
Proportions are presented for categorical data, median with IQR for all continuous data.
Abbreviations: ASA: American Society of Anesthesiologists, BMI: Body Mass Index (kg/m2)